The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC CLL 2026 | Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo, MD, PhD, University of Barcelona, Barcelona, Spain, discusses the genomic landscape of chronic lymphocytic leukemia (CLL) and notes that the high number of different mutations present in very few patients is a unique feature of this disease. Prof. Campo suggests that the heterogeneity may reflect distinct subtypes of the disease, with groups of mutations marking subtypes that differ biologically and, to a lesser extent, clinically. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
